Abstract
In this study, we found miR-362-5p was upregulated in bladder cancer tissues and we predicted that QKI is potential a target of miR-362-5p and MBNL1-AS1 might be able to directly target to miR-362-5p. We attempted to evaluate whether miR-362-5p could play its roles in bladder cancer through regulating QKI (quaking) and whether the expression and function of miR-362-5p could be mediated by lncRNA MBNL1-AS1. We performed the gain- and loss-function experiments to explore the association between miR-362-5p expression and bladder cancer proliferation. In vivo, the nude mice were injected with miR-362-5p knockdown SW780 cells to assess the effects of miR-362-5p on tumor growth. The results showed upregulation of miR-362-5p promoted cell proliferation of bladder cancer cells. MBNL1-AS1 and QKI could directly bind with miR-362-5p, and knockdown of MBNL1-AS1 or QKI could abrogate the regulatory effects of miR-362-5p on bladder cancer cell proliferation. Furthermore, downregulation of miR-362-5p inhibited bladder tumor growth and increased QKI expression. Our data unveiled that miR-362-5p may play an oncogenic role in bladder cancer through QKI and MBNL1-AS1 might function as a sponge to mediate the miR-362-5p expression and function.
Highlights
Bladder cancer is a common urological malignancy worldwide in the urinary system and occurs more frequently in men than women (Ferlay et al, 2015; Antoni et al, 2017)
To investigate the effect of miR-362-5p on the proliferation of bladder cancer cells, the 5637 cells were transfected with miR-362-5p mimic or NC mimic, and SW780 cells were transfected with miR-362-5p inhibitor or NC inhibitor
The results show that upregulation of miR-362-5p could promote G1/S transition in the progression of cell cycle, whereas downregulation of miR-362-5p arrested the cell at G1 phase (Figures 2E, F)
Summary
Bladder cancer is a common urological malignancy worldwide in the urinary system and occurs more frequently in men than women (Ferlay et al, 2015; Antoni et al, 2017). Therapeutic methods are transurethral resection of the bladder tumor for NMIBCs and radical cystectomy for MIBCs. the bladder cancer has a high rate of recurrence. The 5–30% of these NMIBCs cases will develop to MIBCs and MIBCs have a poor 5-year overall survival (approximately 15–70%) (Shabsigh et al, 2009; Prasad et al, 2011; Knowles and Hurst, 2015). A better understanding of the molecular mechanisms underlying carcinogenesis and progression is needed for bladder cancer
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
